PALM Intranet

Application Number SEARCH

IDS Flag Clearance for Application 10634709

IDS Information

Content	Mailroom Date	Entry Number	IDS Review	Reviewer
M844	03-08-2004	10	☑	08-10-2005 23:55:40 IDS CONV
M844	07-20-2005	13	☑	08-10-2005 23:55:40 IDS CONV
M844	10-17-2005	21	☑	10-27-2005 16:14:56 tbarden
M844	12-09-2005	22	☑	12-28-2005 10:06:58 gtrammell

UPDATE

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	509	(546/268.1).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/01/07 16:24
L2	525	(546/268.4).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/01/07 16:24
L3	1293	(514/340).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/01/07 16:25
L4	1240	(514/341).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/01/07 16:25
L5	917	(514/342).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/01/07 16:25
L6	31	Amy.inv. and Bunker.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/01/07 16:26
L7	319	Mark.inv. and Morris.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/01/07 16:27
L8	222	Patrick.inv. and Obrien.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/01/07 16:27
L9	53	metalloproteinase and (6 or 7 or 8)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/01/07 16:28

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	509	(546/268.1).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/01/07 16:24
L2	525	(546/268.4).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/01/07 16:24
L3	1293	(514/340).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/01/07 16:25
L4	1240	(514/341).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/01/07 16:25
L5	917	(514/342).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/01/07 16:25
L6	31	Amy.inv. and Bunker.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/01/07 16:26
L7	319	Mark.inv. and Morris.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/01/07 16:27
L8	222	Patrick.inv. and Obrien.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/01/07 16:27
L9	53	metalloproteinase and (6 or 7 or 8)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/01/07 16:28

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611bxv

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	4	OCT 03	MATHDI removed from STN
NEWS	5	OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS	6	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS	7	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS	8	OCT 27	Free KWIC format extended in full-text databases
NEWS	9	OCT 27	DIOGENES content streamlined
NEWS	10	OCT 27	EPFULL enhanced with additional content
NEWS	11	NOV 14	CA/CAplus - Expanded coverage of German academic research
NEWS	12	NOV 30	REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data
NEWS	13	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS	14	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS	15	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS	16	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS	17	DEC 16	MARPATprev will be removed from STN on December 31, 2005
NEWS	18	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS	19	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
http://download.cas.org/express/v8.0-Discover/

NEWS DCOST SINCE APPROXIMATELY 20:00 COLUMBUS TIME DECEMBER 29,
SOME ONLINE COST DISPLAYS HAVE BEEN SHOWING COSTS IN
2006 PRICES FOR STN COLUMBUS FILES. THIS HAS BEEN
CORRECTED. PLEASE BE ASSURED THAT YOU WILL BE BILLED
ACCORDING TO 2005 PRICES UNTIL JAN 1. PLEASE CONTACT
YOUR LOCAL HELP DESK IF YOU HAVE ANY QUESTIONS. WE
APOLOGIZE FOR THE ERROR.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:50:30 ON 07 JAN 2006

=> ile reg
ILE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:50:39 ON 07 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JAN 2006 HIGHEST RN 871301-42-7
DICTIONARY FILE UPDATES: 5 JAN 2006 HIGHEST RN 871301-42-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\106347094.str



chain nodes :
7 9 23 25 26 27 28 30 31 32 33 34 35 36 37 43 44 45 46 47 49
50 51 52
ring nodes :
1 2 3 4 5 6 11 12 13 14 15 16 17 18 19 20 21 22
chain bonds :
2-25 3-52 5-51 6-50 7-9 7-23 12-44 13-30 14-45 16-43 18-49 19-47 20-34
21-46 25-26 25-27 27-28 30-31 30-32 32-33 34-35 34-36 36-37
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16 17-18
17-22 18-19 19-20 20-21 21-22
exact/norm bonds :
3-52 5-51 6-50 7-9 7-23 12-44 14-45 16-43 18-49 19-47 21-46 25-26 25-27
27-28 30-31 30-32 32-33 34-35 34-36 36-37
exact bonds :
2-25 13-30 20-34
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16 17-18
17-22 18-19 19-20 20-21 21-22
isolated ring systems :
containing 1 : 11 : 17 :

G1:H,Cy,Ak

G2:[*1],[*2],[*3]

G3:H,F,CH3,CF3,OH,MeO,CN,CHO

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 9:CLASS 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 23:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 30:CLASS 31:CLASS
32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 43:CLASS 44:CLASS
45:CLASS 46:CLASS 47:CLASS 49:CLASS 50:CLASS 51:CLASS 52:CLASS
Generic attributes :
7:
Saturation : Unsaturated

Number of Carbon Atoms : less than 7
Number of Hetero Atoms : less than 2
Type of Ring System : Monocyclic

Element Count :
Node 7: Limited
C,C4
N,N4
O,O1
S,S1

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,Cy,Ak

G2 [@1],[@2],[@3]

G3 H,F,Me,CF3,OH,MeO,CN,CHO

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:51:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 13706 TO ITERATE

14.6% PROCESSED 2000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 267107 TO 281133
PROJECTED ANSWERS: 52 TO 496

L2 2 SEA SSS SAM L1

=> d scan

L2 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Pyridinecarboxamide, N-(3-bromophenyl)-3-hydroxy-4-(1H-pyrrol-1-yl)-(9CI)
MF C16 H12 Br N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Pyridinecarboxamide, N-[(4-fluorophenyl)methyl]-3-hydroxy-4-(2-thienyl)-(9CI)
MF C17 H13 F N2 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss ful
FULL SEARCH INITIATED 14:51:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 274136 TO ITERATE

100.0% PROCESSED 274136 ITERATIONS 112 ANSWERS
SEARCH TIME: 00.00.06

L3 112 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 167.38 167.59

FILE 'CAPLUS' ENTERED AT 14:51:46 ON 07 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 7 Jan 2006 VOL 144 ISS 3
FILE LAST UPDATED: 6 Jan 2006 (20060106/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 36 L3

=> d l4 1-36 bib hitstr

L4 ANSWER 1 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1262794 CAPLUS
DN 144:6680
TI Preparation of substituted (arylacyl)thioureas, their use as antiviral agents, and method for prophylactic or therapeutic treatment of hepatitis C
IN Phadke, Avinashi; Chen, Dawei; Deshpande, Milind; Thurkauf, Andrew; Wang, Xiangzhu; Shen, Yiping; Liu, Cuixian; Quinn, Jesse; Okanda, Junko; Lee, Shouming
PA Achillion Pharmaceuticals, Inc., USA
SO Jpn. Kokai Tokkyo Koho, 186 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2005330284	A2	20051202	JP 2005-144790	20050517
PRAI US 2004-572156P	P	20040518		

IT **870145-40-7P 870145-42-9P 870145-44-1P 870145-46-3P 870145-48-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (arylacyl)thioureas as antiviral agents for treatment of hepatitis C)
RN 870145-40-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 870145-42-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 870145-44-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 870145-46-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 870145-48-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



L4 ANSWER 2 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1103772 CAPLUS
DN 143:386909
TI Substituted thiophene derivatives as anti-cancer agents, and their preparation, pharmaceutical compositions, and use as inhibitors of PKB/Akt, PKA, and CDC7.
IN Lin, Xiaodong; Rico, Alice; Zhou, Yasheen; Jefferson, Ann B.; Walter, Annette
PA Chiron Corporation, USA; Wang, Xiaojing Michael
SO PCT Int. Appl., 245 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005095386	A1	20051013	WO 2005-US10690	20050330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005256121	A1	20051117	US 2005-95993	20050330
PRAI US 2004-558342P	P	20040330		

IT **866523-60-6P**, 4-[5-[[[2-(4-Fluorophenyl)ethyl]amino]carbonyl]thien-2-yl]pyridine-2-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of substituted thiophene derivs. as PKB/Akt, PKA, and CDC7 inhibitors for treatment of cancer)
RN 866523-60-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[5-[[[2-(4-fluorophenyl)ethyl]amino]carbonyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:409512 CAPLUS
DN 142:463613
TI A preparation of pyridinecarboxamide derivatives, useful for inhibiting HIV integrase
IN Kong, Laval Chan Chun; Zhang, Ming-Qiang; Halab, Liliane; Nguyen-Ba, Nghe; Liu, Bingcan
PA Virochem Pharma Inc., Can.
SO PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005042524	A1	20050512	WO 2004-CA1898	20041029
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005176767	A1	20050811	US 2004-976238	20041029
PRAI US 2003-515443P	P	20031030		

OS MARPAT 142:463613
IT **851441-87-7P**, 3-Hydroxy-4-thiophen-2-ylpyridine-2-carboxylic acid 4-fluorobenzylamide **851441-88-8P**, 4-Furan-2-yl-3-hydroxypyridine-2-carboxylic acid 4-fluorobenzylamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridinecarboxamide derivs. useful for inhibiting HIV integrase)
RN 851441-87-7 CAPLUS
CN 2-Pyridinecarboxamide, N-[(4-fluorophenyl)methyl]-3-hydroxy-4-(2-thienyl)-(9CI) (CA INDEX NAME)



RN 851441-88-8 CAPLUS
CN 2-Pyridinecarboxamide, N-[(4-fluorophenyl)methyl]-4-(2-furanyl)-3-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:1037072 CAPLUS
DN 142:23183
TI Preparation of sulfopyrroles as apoptosis inducers for the treatment of neoplastic and autoimmune diseases
IN Eberle, Martin; Obrecht, Daniel; Ermert, Philipp; Lach, Franck; Luther, Anatol; Bachmann, Felix; Strebel, Alessandro
PA Aponetics A.-G., Switz.
SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004103968	A1	20041202	WO 2004-IB1818	20040524

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI EP 2003-405380 A 20030526
OS MARPAT 142:23183
IT **800383-87-3P 800383-90-8P 800383-93-1P**
800383-98-6P 800383-99-7P 800384-00-3P
800384-01-4P 800384-10-5P 800384-46-7P
800384-47-8P 800384-48-9P 800384-49-0P
800384-50-3P 800384-52-5P 800384-53-6P
800384-54-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of sulfonylpyrroles as apoptosis inducers for treatment of neoplastic and autoimmune diseases)
RN 800383-87-3 CAPLUS
CN 3-Pyridinecarboxamide, 5-[5-(1,3-benzodioxol-5-yl)-1-[(4-methylphenyl)sulfonyl]-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)



RN 800383-90-8 CAPLUS
CN 3-Pyridinecarboxamide, 5-[1-[(4-methylphenyl)sulfonyl]-5-(2-thienyl)-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)



RN 800383-93-1 CAPLUS
CN 3-Pyridinecarboxamide, 5-[1-[(4-methylphenyl)sulfonyl]-5-(3,4,5-trimethoxyphenyl)-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)



RN 800383-98-6 CAPLUS
CN 3-Pyridinecarboxamide, 5-[1-[(4-methylphenyl)sulfonyl]-5-(3,4,5-trimethoxyphenyl)-1H-pyrrol-3-yl]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 800383-99-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-hydroxy-1-methylethyl)-5-[1-[(4-methylphenyl)sulfonyl]-5-(3,4,5-trimethoxyphenyl)-1H-pyrrol-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 800384-00-3 CAPLUS
CN 3-Pyridinecarboxamide, 5-[1-[(4-methylphenyl)sulfonyl]-5-(3,4,5-trimethoxyphenyl)-1H-pyrrol-3-yl]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 800384-01-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(3-methoxypropyl)-5-[1-[(4-methylphenyl)sulfonyl]-5-(3,4,5-trimethoxyphenyl)-1H-pyrrol-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 800384-10-5 CAPLUS
CN 3-Pyridinecarboxamide, 5-[5-(1,3-benzodioxol-5-yl)-1-[(3-chlorophenyl)sulfonyl]-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)



RN 800384-46-7 CAPLUS
CN 3-Pyridinecarboxamide, 5-[1-[(4-methoxyphenyl)sulfonyl]-5-(3,4,5-trimethoxyphenyl)-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)



RN 800384-47-8 CAPLUS
CN 3-Pyridinecarboxamide, 5-[5-(2,5-dimethoxyphenyl)-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)



RN 800384-48-9 CAPLUS
CN 3-Pyridinecarboxamide, 5-[5-(2,4-dimethoxyphenyl)-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)



RN 800384-49-0 CAPLUS
CN 3-Pyridinecarboxamide, 5-[5-(2-methoxyphenyl)-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)



RN 800384-50-3 CAPLUS
CN 3-Pyridinecarboxamide, 5-[1-[(4-methylphenyl)sulfonyl]-5-(3,4,5-trimethoxyphenyl)-1H-pyrrol-3-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 800384-52-5 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-hydroxy-1-methylethyl)-5-[1-[(4-methylphenyl)sulfonyl]-5-(3,4,5-trimethoxyphenyl)-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)



RN 800384-53-6 CAPLUS
CN 3-Pyridinecarboxamide, 5-[1-[(4-methylphenyl)sulfonyl]-5-(3,4,5-trimethoxyphenyl)-1H-pyrrol-3-yl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 800384-54-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(3-methoxypropyl)-5-[1-[(4-methylphenyl)sulfonyl]-5-(3,4,5-trimethoxyphenyl)-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:963181 CAPLUS
DN 141:379941
TI Preparation of quinazoline-2,4-diamines as melanin concentrating hormone (MCH) receptor antagonists
IN Sekiguchi, Yoshikatsu; Kanuma, Yukihiro; Omodera, Katsunori; Tran, Thuy-ahn; Kramer, Bryan Aubrey; Beeley, Nigel Robert Arnold
PA Taisho Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 988 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2004315511	A2	20041111	JP 2004-95046	20040329
PRAI	JP 2003-93418	A	20030331		

OS MARPAT 141:379941

IT **509141-97-3P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazoline derivs. as melanin-concentrating hormone (MCH) receptor antagonists for prevention and/or treatment of obesity, obesity-related diseases, anxiety, or depression)

RN 509141-97-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[[4-(dimethylamino)-2-quinazolinyl]amino]phenyl]-5-(2-thienyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 509141-96-2

CMF C26 H22 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L4 ANSWER 6 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:902333 CAPLUS

DN 141:379916

TI Novel hydroxamates as histone deacetylase inhibitors, process for their preparations, pharmaceutical compositions and uses in the treatment of cancer and hepatitis C

IN Verner, Eric J.; Sendzik, Martin; Baskaran, Chitra; Buggy, Joseph J.; Robinson, James

PA Axys Pharmaceuticals Inc., USA

SO PCT Int. Appl., 149 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004092115	A2	20041028	WO 2004-US10549	20040406
	WO 2004092115	A3	20050217		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2521647	AA	20041028	CA 2004-2521647	20040406
	US 2005187261	A1	20050825	US 2004-818755	20040406
	EP 1611088	A2	20060104	EP 2004-749791	20040406
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-461286P	P	20030407		
	US 2003-464448P	P	20030421		
	WO 2004-US10549	W	20040406		

OS MARPAT 141:379916

IT **783354-90-5P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of novel hydroxamates as histone deacetylase inhibitors for the treatment of cancer and hepatitis C)

RN 783354-90-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-5-(3-thienyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:700281 CAPLUS

DN 141:207064

TI Preparation of heteroarylcarboxamides as fungicides

IN Mansfield, Darren James; Rieck, Heiko; Greul, Joerg Nico; Coqueron, Pierre-Yves; Desbordes, Philippe; Genix, Pierre; Grosjean-Cournoyer, Marie-Claire; Perez, Joseph; Villier, Alain

PA Bayer Cropscience Sa, Fr.

SO Eur. Pat. Appl., 46 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1449841	A1	20040825	EP 2003-356029	20030219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CA 2516186	AA	20040902	CA 2004-2516186	20040212
	WO 2004074280	A1	20040902	WO 2004-EP2381	20040212
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1597252	A1	20051123	EP 2004-710397	20040212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	EP 2003-356029	A	20030219		
	WO 2004-EP2381	W	20040212		

OS MARPAT 141:207064

IT **743456-04-4P**

RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(fungicide; preparation of heteroarylcarboxamides as fungicides)

RN 743456-04-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]ethyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:534176 CAPLUS

DN 141:89017

TI A preparation of nicotinamide-based tyrosine kinase inhibitors

IN Burns, Christopher John; Kling, Marcel Robert

PA Cytopia Pty. Ltd., Australia

SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004054977	A1	20040701	WO 2003-AU1666	20031215
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2508171	AA	20040701	CA 2003-2508171	20031215
	EP 1569907	A1	20050907	EP 2003-767297	20031215
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	AU 2002-953330	A	20021213		
	AU 2002-953385	A	20021217		
	US 2003-483400P	P	20030626		
	WO 2003-AU1666	W	20031215		

OS MARPAT 141:89017

IT **713520-49-1P 713520-56-0P 713520-61-7P**
713520-67-3P 713523-01-4P 713523-02-5P
713523-03-6P 713523-04-7P 713523-05-8P
713523-06-9P 713523-07-0P 713523-08-1P
713523-09-2P 713523-10-5P 713523-11-6P
713523-12-7P 713523-13-8P 713523-14-9P
713523-15-0P 713523-16-1P 713523-17-2P
713523-18-3P 713523-19-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nicotinamide-based kinase inhibitors)

RN 713520-49-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[(1S)-1-phenylethyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 713520-56-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713520-61-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-furanylmethyl)-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713520-67-3 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-N-(phenylmethyl)-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713523-01-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(4-morpholinyl)phenyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713523-02-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[(1R)-1-phenylethyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 713523-03-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713523-04-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-(hydroxymethyl)-2-methylpropyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713523-05-8 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-hydroxyethyl)-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713523-06-9 CAPLUS
CN 3-Pyridinecarboxamide, N-phenyl-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713523-07-0 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-pyridinylmethyl)-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713523-08-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[(3-fluorophenyl)methyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713523-09-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(1-methylethyl)-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713523-10-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-methylphenyl)methyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713523-11-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-phenylethyl)-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713523-12-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(2,5-dimethylphenyl)-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713523-13-8 CAPLUS
CN 3-Pyridinecarboxamide, N-(5-fluoro-2-methylphenyl)-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713523-14-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-fluoro-2-methylphenyl)-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713523-15-0 CAPLUS
CN 3-Pyridinecarboxamide, N-(1-methyl-3-phenylpropyl)-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713523-16-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(2,4-dimethoxyphenyl)-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713523-17-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-methylphenyl)-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713523-18-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-(4-fluorophenyl)ethyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 713523-19-4 CAPLUS

CN 3-Pyridinecarboxamide, 5-(2-thienyl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:523110 CAPLUS
DN 141:71536
TI Preparation of 2-(5-phosphono)furanyl substituted heteroaromatic compounds as fructose-1,6-bisphosphatase (FBPase) inhibitors for use in combination with insulin sensitizers for the treatment of diabetes
IN Erion, Mark D.; Van Poelje, Paul D.
PA Metabasis Therapeutics, Inc., USA
SO U.S., 109 pp., Cont.-in-part of U.S. Provisional Ser. No. 114,718.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6756360	B1	20040629	US 1999-470649	19991222
	EP 1552850	A2	20050713	EP 2005-8493	19991222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	ZA 2001005016	A	20020919	ZA 2001-5016	20010619
	US 2004167178	A1	20040826	US 2004-780948	20040217
PRAI	US 1998-114718P	P	19981224		
	EP 1999-964313	A3	19991222		
	US 1999-470649	A3	19991222		

OS MARPAT 141:71536
IT **261371-03-3P 280782-53-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-(5-phosphono)furanyl substituted thiazoles as fructose-1,6-bisphosphatase inhibitors for use in combination with insulin sensitizer for treating diabetes)
RN 261371-03-3 CAPLUS
CN Phosphonic acid, [5-[4-(aminocarbonyl)-6-methoxy-2-pyridinyl]-2-furanyl]- (9CI) (CA INDEX NAME)



RN 280782-53-8 CAPLUS
CN Phosphonic acid, [5-[4-(aminocarbonyl)-1,6-dihydro-6-oxo-2-pyridinyl]-2-furanyl]- (9CI) (CA INDEX NAME)



RE.CNT 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:493569 CAPLUS
DN 141:54199
TI Preparation of nicotinamide derivatives and method of inhibiting angiogenesis
IN Haviv, Fortuna; Bradley, Michael F.; Dinges, Jurgen; Sauer, Daryl R.; Henkin, Jack
PA USA
SO U.S. Pat. Appl. Publ., 38 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004116479	A1	20040617	US 2003-678771	20031003
PRAI US 2002-416028P	P	20021004		

OS MARPAT 141:54199
IT **676532-93-7P**, N,N-Diethyl-5-(3-furyl)nicotinamide
676534-80-8P, N,N-Diethyl-5-(3-furyl)nicotinamide trifluoroacetate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nicotinamide derivs. as angiogenesis inhibitors and anticancer agents)
RN 676532-93-7 CAPLUS
CN 3-Pyridinecarboxamide, N,N-diethyl-5-(3-furanyl)- (9CI) (CA INDEX NAME)



RN 676534-80-8 CAPLUS
CN 3-Pyridinecarboxamide, N,N-diethyl-5-(3-furanyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676532-93-7
CMF C14 H16 N2 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L4 ANSWER 11 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:453614 CAPLUS
DN 141:173950
TI A Fluorous-Tagged, Acid-Labile Protecting Group for the Synthesis of Carboxamides and Sulfonamides
AU Villard, Anne-Laure; Warrington, Brian H.; Ladlow, Mark
CS University Chemical Laboratory, GlaxoSmithKline Cambridge Technology Centre, Cambridge, CB2 1EW, UK
SO Journal of Combinatorial Chemistry (2004), 6(4), 611-622
CODEN: JCCHFF; ISSN: 1520-4766
PB American Chemical Society
DT Journal
LA English
OS CASREACT 141:173950
IT **734549-14-5P 734549-20-3P 734549-26-9P**
RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant

or reagent)
(N-deprotection; parallel solution-phase synthesis of carboxamides and sulfonamides using a fluorous-tagged acid-labile protecting group)

RN 734549-14-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[(4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-heptadecafluoroundecyl)oxy]-2-methoxyphenyl]methyl]-N-[(4-methylphenyl)methyl]-5-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 734549-20-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[(4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-heptadecafluoroundecyl)oxy]-2-methoxyphenyl]methyl]-N-(2-phenylethyl)-5-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 734549-26-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[(4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-heptadecafluoroundecyl)oxy]-2-methoxyphenyl]methyl]-5-(3-thienyl)-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



IT **734549-32-7P 734549-38-3P 734549-44-1P**
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(parallel solution-phase synthesis of carboxamides and sulfonamides using a fluorous-tagged acid-labile protecting group)

RN 734549-32-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-methylphenyl)methyl]-5-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 734549-38-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-phenylethyl)-5-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 734549-44-1 CAPLUS
CN 3-Pyridinecarboxamide, 5-(3-thienyl)-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:293391 CAPLUS
DN 140:303548
TI Preparation of nicotinamide derivatives and method of inhibiting angiogenesis
IN Haviv, Fortuna; Bradley, Michael F.; Dinges, Jurgen; Sauer, Daryl R.; Henkin, Jack
PA USA
SO U.S. Pat. Appl. Publ., 38 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004067985	A1	20040408	US 2002-264421	20021004
	CA 2501043	AA	20040422	CA 2003-2501043	20031002
	WO 2004032908	A2	20040422	WO 2003-US31220	20031002
	WO 2004032908	C2	20040527		
	WO 2004032908	A3	20040812		
	W: CA, JP, MX				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	EP 1551404	A2	20050713	EP 2003-773094	20031002
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-264421	A	20021004		
	WO 2003-US31220	W	20031002		

OS MARPAT 140:303548
IT **676532-93-7P**, N,N-Diethyl-5-(3-furyl)nicotinamide
676534-80-8P, N,N-Diethyl-5-(3-furyl)nicotinamide trifluoroacetate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nicotinamide derivs. as angiogenesis inhibitors and anticancer agents)
RN 676532-93-7 CAPLUS
CN 3-Pyridinecarboxamide, N,N-diethyl-5-(3-furanyl)- (9CI) (CA INDEX NAME)



RN 676534-80-8 CAPLUS
CN 3-Pyridinecarboxamide, N,N-diethyl-5-(3-furanyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676532-93-7
CMF C14 H16 N2 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L4 ANSWER 13 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:182843 CAPLUS
DN 140:235498
TI Preparation of antibacterial benzoic acid derivatives
IN Thorarensen, Atli; Ruble, Craig J.; Fisher, Jed F.; Romero, Donna L.; Beauchamp, Thomas J.; Northuis, Jill M.
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 500 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004018428	A1	20040304	WO 2003-US24796	20030822

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004110802 A1 20040610 US 2003-645802 20030820
PRAI US 2002-405429P P 20020823
US 2002-430592P P 20021203
OS MARPAT 140:235498
IT **668976-08-7P 668976-12-3P**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoic acid derivs. as antibacterial agents)
RN 668976-08-7 CAPLUS
CN Benzoic acid, 5-cyano-2-[[[5-(1-methyl-1H-pyrrol-2-yl)-3-pyridinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 668976-12-3 CAPLUS
CN Benzoic acid, 5-cyano-2-[[[5-(2-furanyl)-3-pyridinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:117213 CAPLUS
DN 140:163868
TI Preparation of acylaminoheteroarenes as upregulators of endothelial nitric oxide synthase (eNOS).
IN Strobel, Hartmut; Wohlfart, Paulus; Below, Peter
PA Aventis Pharma Deutschland GmbH, Germany
SO Eur. Pat. Appl., 40 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1388341	A1	20040211	EP 2002-17585	20020807
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CA 2494298	AA	20040219	CA 2003-2494298	20030724
	WO 2004014369	A1	20040219	WO 2003-EP8102	20030724
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1534275	A1	20050601	EP 2003-784054	20030724
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013294	A	20050712	BR 2003-13294	20030724
	JP 2005538123	T2	20051215	JP 2004-526764	20030724
	US 2004110808	A1	20040610	US 2003-634979	20030805
PRAI	EP 2002-17585	A	20020807		
	US 2002-432314P	P	20021210		
	WO 2003-EP8102	W	20030724		

OS MARPAT 140:163868
IT **656251-59-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylaminoheteroarenes as upregulators of endothelial nitric oxide synthase)
RN 656251-59-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-methoxy-2-benzothiazolyl)-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:892800 CAPLUS
DN 139:395950
TI Preparation of substituted pyrazines as protein kinase modulators
IN Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai, Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn, Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John M.; Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepp, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Esther; Forsyth, Thimothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy
PA Exelixis, Inc., USA
SO PCT Int. Appl., 468 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003093297	A2	20031113	WO 2003-US13869	20030502
	WO 2003093297	A3	20040701		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2484209	AA	20031113	CA 2003-2484209	20030502
	EP 1501514	A2	20050202	EP 2003-728690	20030502
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005530760	T2	20051013	JP 2004-501436	20030502
PRAI	US 2002-377933P	P	20020503		
	WO 2003-US13869	W	20030502		

OS MARPAT 139:395950
IT **625468-88-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of protein kinase modulators)
RN 625468-88-4 CAPLUS
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[[5-(2-thienyl)-3-pyridinyl]carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 16 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:696676 CAPLUS
DN 139:230767
TI Preparation of dioxothiazolidinemethylidenefurylbenzenes as common ligand mimics
IN Yu, Lin; Dong, Qing; Pierre, Fabrice; Chang, Edcon; Lang, Hengyuan; Qin, Yong; Fang, Yunfeng; Hansen, Mark R.; Pellecchia, Maurizio
PA Triad Therapeutics, Inc., USA
SO PCT Int. Appl., 336 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003072033	A2	20030904	WO 2003-US5225	20030219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004009526	A1	20040115	US 2002-81989	20020221
	US 2005042674	A9	20050224		
PRAI	US 2002-81989	A	20020221		

OS MARPAT 139:230767
IT **590363-61-4P**, 5-[5-(2,4-Dioxothiazolidin-5-ylidenemethyl)furan-2-yl]-N-(3-hydroxypropyl)nicotinamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dioxothiazolidinemethylidenefurylbenzenes as common ligand mimics)
RN 590363-61-4 CAPLUS
CN 3-Pyridinecarboxamide, 5-[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-2-furanyl]-N-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)



IT **590363-60-3P**, 5-(5-Formylfuran-2-yl)-N-(3-hydroxypropyl)nicotinamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dioxothiazolidinemethylidenefurylbenzenes as common ligand mimics)
RN 590363-60-3 CAPLUS
CN 3-Pyridinecarboxamide, 5-(5-formyl-2-furanyl)-N-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:282325 CAPLUS
DN 138:321285
TI Preparation of quinazoline-2,4-diamines as MCH receptor antagonists
IN Sekiguchi, Yoshinori; Kanuma, Kosuke; Omodera, Katsunori; Tran, Thuy-anh; Kramer, Bryan Aubrey; Beeley, Nigel Robert Arnold
PA Taisho Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 1171 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003028641	A2	20030410	WO 2002-US31059	20020930
	WO 2003028641	A3	20030828		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2460594	AA	20030410	CA 2002-2460594	20020930
	EP 1432693	A2	20040630	EP 2002-800388	20020930

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

JP 2005523237 T2 20050804 JP 2003-531977 20020930

PRAI US 2001-326463P P 20011001

US 2001-326758P P 20011002

WO 2002-US31059 W 20020930

OS MARPAT 138:321285

IT **509141-97-3P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazoline-2,4-diamines as MCH receptor antagonists)

RN 509141-97-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[[4-(dimethylamino)-2-quinazolinyl]amino]phenyl]-5-(2-thienyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 509141-96-2

CMF C26 H22 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L4 ANSWER 18 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:58080 CAPLUS

DN 138:106603

TI Preparation of 4-substituted-picolinic acid amide derivatives useful as agrochemical fungicides

IN Hutin, Pierre; Muller, Benoit; Steele, Christopher Richard; Perez, Joseph; Genix, Pierre

PA Aventis CropScience SA, Fr.

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 2003006456	A1	20030123	WO 2002-EP8665	20020705
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	FR 2827286	A1	20030117	FR 2001-9195	20010711
	EP 1404666	A1	20040407	EP 2002-747474	20020705
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2004534098	T2	20041111	JP 2003-512228	20020705
	US 2004142977	A1	20040722	US 2004-483513	20040322
	US 6953807	B2	20051011		
PRAI	FR 2001-9195	A	20010711		
	WO 2002-EP8665	W	20020705		

OS MARPAT 138:106603

IT **488728-90-1P**, 2-[[[4-(4-(Trifluoromethyl)phenoxy)phenyl]amino]carbonyl]-3-hydroxy-4-(2,5-dimethylpyrrol-1-yl)pyridine **488728-91-2P**, 2-[[[4-(3-(Trifluoromethyl)phenoxy)phenyl]amino]carbonyl]-3-hydroxy-4-(pyrrol-1-yl)pyridine **488729-65-3P**, N-(4-(4-(Trifluoromethyl)phenoxy)phenyl)-3-hydroxy-4-(pyrrol-1-yl)pyridine-2-carboxamide **488729-66-4P**, N-(4-Butoxyphenyl)-3-hydroxy-4-(pyrrol-1-yl)pyridine-2-carboxamide **488729-67-5P**, N-(4-Phenoxyphenyl)-3-hydroxy-4-(2,5-dimethylpyrrol-1-yl)pyridine-2-carboxamide **488729-68-6P**, N-(4-(3-(Trifluoromethyl)phenoxy)phenyl)-3-hydroxy-4-(2,5-dimethylpyrrol-1-yl)pyridine-2-carboxamide **488729-72-2P**, N-(4-(4-(Trifluoromethyl)phenoxy)phenyl)-3-methoxy-4-(pyrrol-1-yl)pyridine-2-carboxamide **488729-74-4P**, N-(4-(3-(Trifluoromethyl)phenoxy)phenyl)-3-methoxy-4-(pyrrol-1-yl)pyridine-2-carboxamide **488729-75-5P**, N-(3-Bromophenyl)-3-hydroxy-4-(pyrrol-1-yl)pyridine-2-carboxamide **488729-76-6P**, N-(4-(4-(Trifluoromethyl)phenoxy)phenyl)-3-methoxy-4-(2,5-dimethylpyrrol-1-yl)pyridine-2-carboxamide **488729-77-7P**, N-(4-(3-(Trifluoromethyl)phenoxy)phenyl)-3-methoxy-4-(2,5-dimethylpyrrol-1-yl)pyridine-2-carboxamide
RL: AGR (Agricultural use); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-substituted-picolinic acid amide derivs. useful as agrochem. fungicides)

RN 488728-90-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-3-hydroxy-N-[4-[4-(trifluoromethyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 488728-91-2 CAPLUS
CN 2-Pyridinecarboxamide, 3-hydroxy-4-(1H-pyrrol-1-yl)-N-[4-[3-(trifluoromethyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 488729-65-3 CAPLUS
CN 2-Pyridinecarboxamide, 3-hydroxy-4-(1H-pyrrol-1-yl)-N-[4-[4-(trifluoromethyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 488729-66-4 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-butoxyphenyl)-3-hydroxy-4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 488729-67-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-3-hydroxy-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 488729-68-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-3-hydroxy-N-[4-[3-(trifluoromethyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 488729-72-2 CAPLUS
CN 2-Pyridinecarboxamide, 3-methoxy-4-(1H-pyrrol-1-yl)-N-[4-[4-(trifluoromethyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 488729-74-4 CAPLUS
CN 2-Pyridinecarboxamide, 3-methoxy-4-(1H-pyrrol-1-yl)-N-[4-[3-(trifluoromethyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 488729-75-5 CAPLUS
CN 2-Pyridinecarboxamide, N-(3-bromophenyl)-3-hydroxy-4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 488729-76-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-3-methoxy-N-[4-[4-(trifluoromethyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 488729-77-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-3-methoxy-N-[4-[3-(trifluoromethyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:921901 CAPLUS
DN 138:4695
TI Preparation of heteroaromatic phosphonates as fructose 1,6-bisphosphatase inhibitors
IN Dang, Qun; Kasibhatla, Srinivas Rao; Reddy, K. Raja; Erion, Mark D.; Reddy, M. Rami; Agarwal, Atul
PA Metabasis Therapeutics, Inc., USA
SO U.S., 129 pp., Cont.-in-part of U.S. Provisional Ser. No. 135,504.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6489476	B1	20021203	US 1999-389698	19990903
	PT 1112275	T	20031231	PT 1999-954595	19990903
	ES 2204170	T3	20040416	ES 1999-954595	19990903
	ZA 2001001711	A	20020528	ZA 2001-1711	20010228
	US 2004058892	A1	20040325	US 2003-636474	20030806
PRAI	US 1998-135504P	P	19980909		
	US 1998-111077P	P	19981207		
	US 1999-389698	A1	19990903		
	US 2002-231953	B1	20020830		

IT **261371-03-3P**, Phosphonic acid, [5-[4-(aminocarbonyl)-6-methoxy-2-pyridinyl]-2-furanyl]-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(target compound; preparation of heteroarom. phosphonates as fructose 1,6-bisphosphatase inhibitors via high throughput and standard synthetic methods)
RN 261371-03-3 CAPLUS
CN Phosphonic acid, [5-[4-(aminocarbonyl)-6-methoxy-2-pyridinyl]-2-furanyl]- (9CI) (CA INDEX NAME)



RE.CNT 85 THERE ARE 85 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:637654 CAPLUS
DN 137:185323
TI Preparation of N-tetrahydronaphthyl (hetero)aranecarboxamides as endothelial NO synthase expression upregulators
IN Strobel, Hartmut; Wohlfart, Paulus
PA Aventis Pharma Deutschland GmbH, Germany
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002064565	A1	20020822	WO 2002-EP1448	20020212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2437950	AA	20020822	CA 2002-2437950	20020212
EP 1370530	A1	20031217	EP 2002-719806	20020212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004518722	T2	20040624	JP 2002-564498	20020212
US 2003022935	A1	20030130	US 2002-73307	20020213
US 6949556	B2	20050927		
PRAI EP 2001-102851	A	20010213		
WO 2002-EP1448	W	20020212		

OS MARPAT 137:185323
IT **449183-16-8P 449183-19-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-tetrahydronaphthyl (hetero)aranecarboxamides as endothelial NO synthase expression upregulators)
RN 449183-16-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449183-19-1 CAPLUS
CN Formic acid, compd. with N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]-5-(2-thienyl)-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449183-18-0
CMF C20 H18 N2 O S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:555497 CAPLUS
DN 137:125392
TI Preparation of N-acyl azabicyclic compounds as inhibitors of cruzipain and

other cysteine proteases
IN Quibell, Martin
PA Incenta Limited, UK
SO PCT Int. Appl., 243 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002057270	A1	20020725	WO 2002-GB184	20020117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2436462	AA	20020725	CA 2002-2436462	20020117
EP 1362052	A1	20031119	EP 2002-732145	20020117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002006501	A	20040113	BR 2002-6501	20020117
JP 2004518674	T2	20040624	JP 2002-557947	20020117
NZ 526913	A	20041224	NZ 2002-526913	20020117
ZA 2003005259	A	20040510	ZA 2003-5259	20030708
NO 2003003220	A	20030917	NO 2003-3220	20030716
US 2004138250	A1	20040715	US 2004-466384	20040108
PRAI GB 2001-1179	A	20010117		
US 2001-275359P	P	20010313		
WO 2002-GB184	W	20020117		

OS MARPAT 137:125392
IT **443897-73-2P 443898-04-2P 443898-75-7P 443898-81-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminocyclopentanecarboxylic acid-derived bicyclic compds. as inhibitors of cruzipain and other cysteine proteases)
RN 443897-73-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[(1S)-2-[(3aS,6aR)-hexahydro-3-oxo-4H-furo[3,2-b]pyrrol-4-yl]-1-[(4-hydroxyphenyl)methyl]-2-oxoethyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 443898-04-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[(1S)-1-[[(3aS,6aR)-hexahydro-3-oxo-4H-furo[3,2-b]pyrrol-4-yl]carbonyl]-3-methylbutyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 443898-75-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[(1S)-2-[(3aS,7aR)-hexahydro-3-oxofuro[3,2-b]pyridin-4(2H)-yl]-1-[(4-hydroxyphenyl)methyl]-2-oxoethyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 443898-81-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[(1S)-1-[[(3aS,7aR)-hexahydro-3-oxofuro[3,2-b]pyridin-4(2H)-yl]carbonyl]-3-methylbutyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:555478 CAPLUS
DN 137:125391
TI Preparation of 4-(acylamino)tetrahydro-3-furanones or -3-thiophenones and 2-(acylamino)cyclopentanones as inhibitors of cruzipain and other cysteine proteases
IN Quibell, Martin
PA Incenta Limited, UK
SO PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002057249	A1	20020725	WO 2002-GB190	20020117

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2435117	AA	20020725	CA 2002-2435117	20020117
EP 1362042	A1	20031119	EP 2002-732147	20020117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004522738	T2	20040729	JP 2002-557930	20020117
NZ 526914	A	20050225	NZ 2002-526914	20020117
ZA 2003005262	A	20040517	ZA 2003-5262	20030708
US 2004127549	A1	20040701	US 2004-466474	20040108
PRAI GB 2001-1187	A	20010117		
US 2001-275505P	P	20010313		
WO 2002-GB190	W	20020117		

OS MARPAT 137:125391

IT **443924-15-0P 443924-22-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (acylamino)tetrahydrofuranones or -thiophenones and -cyclopentanones as inhibitors of cruzipain and other cysteine proteases)

RN 443924-15-0 CAPLUS
CN D-erythro-2-Pentulose, 1,4-anhydro-3,5-dideoxy-3-[[(2S)-3-(4-hydroxyphenyl)-1-oxo-2-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]amino]propyl]amino]-3-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 443924-22-9 CAPLUS
CN D-erythro-2-Pentulose, 1,4-anhydro-3,5-dideoxy-3-C-methyl-3-[[(2S)-4-methyl-1-oxo-2-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]amino]pentyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:369952 CAPLUS
DN 137:332733
TI Identification of phenyl-pyridine-2-carboxylic acid derivatives as novel cell cycle inhibitors with increased selectivity for cancer cells
AU Berthel, Steven J.; Marks, Ian M.; Yin, Xuefeng; Mischke, Steven G.; Orzechowski, Lucja; Pezzoni, Gabriella; Sala, Franca; Vassilev, Lyubomir T.
CS Discovery Chemistry, Roche Research Center, Hoffmann-La Roche Inc, Nutley, NJ, 07110, USA
SO Anti-Cancer Drugs (2002), 13(4), 359-366
CODEN: ANTDEV; ISSN: 0959-4973
PB Lippincott Williams & Wilkins
DT Journal
LA English
OS CASREACT 137:332733
IT **473796-58-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(identification of Ph-pyridine-2-carboxylic acid derivs. as novel cell cycle inhibitors with increased selectivity for cancer cells)
RN 473796-58-6 CAPLUS
CN 2-Pyridinecarboxamide, N-(2-aminoethyl)-4-(3-thienyl)- (9CI) (CA INDEX NAME)



IT **721401-12-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(identification of Ph-pyridine-2-carboxylic acid derivs. as novel cell cycle inhibitors with increased selectivity for cancer cells)
RN 721401-12-3 CAPLUS
CN Carbamic acid, [2-[[[4-(3-thienyl)-2-pyridinyl]carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:1464 CAPLUS
DN 136:363245
TI Synthesis and structure-activity relationships of oxime neurokinin antagonists: discovery of potent arylamides
AU Shih, Neng-Yang; Albanese, Margaret; Anthes, John C.; Carruthers, Nicholas I.; Grice, Cheryl A.; Lin, Ling; Mangiaracina, Pietro; Reichard, Gregory A.; Schwerdt, John; Seidl, Vera; Wong, Shing-Chung; Piwinski, John J.
CS Schering-Plough Research Institute, Kenilworth, NJ, 07033-1300, USA
SO Bioorganic & Medicinal Chemistry Letters (2002), 12(2), 141-145
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
IT **425368-66-7**
RL: BCP (Biochemical process); PAC (Pharmacological activity); BIOL (Biological study); PROC (Process)
(neurokinin antagonistic structure-activity relationship of 1-[5-[3,5-bis(trifluoromethyl)phenyl]-3-(3,4-dichlorophenyl)-5-(methoxyimino)pentyl]-4-phenyl-4-piperidinol analogs and derivs.)
RN 425368-66-7 CAPLUS
CN 4-Pyridinecarboxamide, N-[3-(3,4-dichlorophenyl)-5-(4-hydroxy-4-phenyl-1-piperidinyl)-2-(methoxyimino)pentyl]-N,2-dimethyl-6-(2-thienyl)- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:676775 CAPLUS
DN 135:211059
TI Preparation of arylheterocycle phosphates as antidiabetics and aryl fructose-1,6-bisphosphatase inhibitors
IN Bookser, Brett C.; Dang, Qun; Reddy, K. Raja

PA Metabasis Therapeutics, Inc., USA
SO PCT Int. Appl., 175 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001066553	A2	20010913	WO 2001-US7452	20010307
	WO 2001066553	A3	20020314		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2401706	AA	20010913	CA 2001-2401706	20010307
	US 2002040014	A1	20020404	US 2001-801933	20010307
	US 6919322	B2	20050719		
	BR 2001009062	A	20021126	BR 2001-9062	20010307
	EP 1265907	A2	20021218	EP 2001-918456	20010307
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003525944	T2	20030902	JP 2001-565369	20010307
	CN 1516705	A	20040728	CN 2001-809021	20010307
	EP 1607401	A1	20051221	EP 2005-15039	20010307
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	ZA 2002007004	A	20031201	ZA 2002-7004	20020830
	NO 2002004240	A	20021108	NO 2002-4240	20020905
	US 2005176684	A1	20050811	US 2005-43859	20050125
PRAI	US 2000-187750P	P	20000308		
	EP 2001-918456	A3	20010307		
	US 2001-801933	A3	20010307		
	WO 2001-US7452	W	20010307		

OS MARPAT 135:211059
IT **358671-42-8P 358671-67-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylheterocycle phosphates as antidiabetics and aryl fructose-1,6-bisphosphatase inhibitors)
RN 358671-42-8 CAPLUS
CN Phosphonic acid, [5-[5-[[[2-(2-hydroxyethyl)phenyl]amino]carbonyl]-3-pyridinyl]-2-furanyl]- (9CI) (CA INDEX NAME)



RN 358671-67-7 CAPLUS
CN Phosphonic acid, [5-[5-[[[(tetrahydro-2-furanyl)methyl]amino]carbonyl]-3-pyridinyl]-2-furanyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:489407 CAPLUS
DN 135:76989
TI Novel bisamidate phosphonate prodrugs of FBPase inhibitors for use as antidiabetics
IN Jaing, Tao; Kasibhatla, Srinivas Rao; Reddy, Raja K.
PA Metabasis Therapeutics, Inc., USA
SO PCT Int. Appl., 250 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047935	A2	20010705	WO 2000-IB2071	20001222
	WO 2001047935	A3	20020321		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2396713	AA	20010705	CA 2000-2396713	20001222
	EP 1240174	A2	20020918	EP 2000-993135	20001222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2000017048	A	20021105	BR 2000-17048	20001222
	US 2002173490	A1	20021121	US 2000-747182	20001222
	US 6965033	B2	20051115		
	JP 2003519154	T2	20030617	JP 2001-549405	20001222
	NZ 519219	A	20040326	NZ 2000-519219	20001222
	ZA 2002004399	A	20030925	ZA 2002-4399	20020531
	NO 2002002932	A	20020822	NO 2002-2932	20020618
	US 2005004077	A1	20050106	US 2004-900718	20040728
PRAI	US 1999-171862P	P	19991222		
	US 2000-747182	A1	20001222		
	WO 2000-IB2071	W	20001222		

OS MARPAT 135:76989

IT **261371-03-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and use of antidiabetic bisamidate phosphonate prodrugs)

RN 261371-03-3 CAPLUS

CN Phosphonic acid, [5-[4-(aminocarbonyl)-6-methoxy-2-pyridinyl]-2-furanyl]-(9CI) (CA INDEX NAME)



L4 ANSWER 27 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:666740 CAPLUS

DN 133:222971

TI Preparation of 6-O-substituted macrolides erythromycin analogs having antibacterial activity

IN Or, Yat Sun; Clark, Richard F.; Ma, Zhenkun; Rupp, Michael J.

PA Abbott Laboratories, USA

SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000055168	A1	20000921	WO 2000-US6033	20000308
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2367431	AA	20000921	CA 2000-2367431	20000308
	EP 1161438	A1	20011212	EP 2000-913805	20000308
	EP 1161438	B1	20040506		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200102522	T2	20011221	TR 2001-200102522	20000308
	BR 2000008731	A	20020924	BR 2000-8731	20000308

	JP 2002539217	T2	20021119	JP 2000-605596	20000308
	NZ 513206	A	20040227	NZ 2000-513206	20000308
	AT 266036	E	20040515	AT 2000-913805	20000308
	PT 1161438	T	20040930	PT 2000-913805	20000308
	ES 2222189	T3	20050201	ES 2000-913805	20000308
	ZA 2001006181	A	20021026	ZA 2001-6181	20010726
	BG 105865	A	20020531	BG 2001-105865	20010901
	NO 2001004380	A	20010910	NO 2001-4380	20010910
PRAI	US 1999-270497	A	19990315		
	WO 2000-US6033	W	20000308		

OS MARPAT 133:222971

IT **263867-83-0P 263867-87-4P 263867-88-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted macrolides erythromycin analogs having antibacterial activity)

RN 263867-83-0 CAPLUS

CN 3-Pyridinecarboxamide, 5-[5-[3-[[(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-ethyltetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propynyl]-2-thienyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 263867-87-4 CAPLUS

CN 3-Pyridinecarboxamide, 5-[5-[3-[[(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-ethyltetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propynyl]-2-thienyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 263867-88-5 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[5-[3-[[(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-ethyltetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propynyl]-2-thienyl]-, 2,2-dimethylhydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:666727 CAPLUS
DN 133:252450
TI Preparation of 3-(3-amidophenyl)-3,4-dihydroquinazolin-4-ones for treating diseases mediated by cytokines
IN Brown, Dearg Sutherland
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000055153	A1	20000921	WO 2000-GB912	20000313
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2368097	AA	20000921	CA 2000-2368097	20000313
	EP 1163237	A1	20011219	EP 2000-909498	20000313
	EP 1163237	B1	20040506		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000009083	A	20020102	BR 2000-9083	20000313
	TR 200103336	T2	20020422	TR 2001-200103336	20000313
	JP 2002539207	T2	20021119	JP 2000-605582	20000313
	AU 761453	B2	20030605	AU 2000-31778	20000313
	AT 266023	E	20040515	AT 2000-909498	20000313
	NZ 514195	A	20040528	NZ 2000-514195	20000313
	PT 1163237	T	20040831	PT 2000-909498	20000313
	ES 2219319	T3	20041201	ES 2000-909498	20000313
	RU 2260007	C2	20050910	RU 2001-128066	20000313
	ZA 2001007536	A	20030818	ZA 2001-7536	20010912
	NO 2001004492	A	20011112	NO 2001-4492	20010914
	HK 1041885	A1	20050128	HK 2002-103785	20020521
	US 2005245551	A1	20051103	US 2005-176327	20050708
PRAI	GB 1999-6279	A	19990317		
	GB 1999-26667	A	19991111		
	WO 2000-GB912	W	20000313		
	US 2001-936758	A3	20011115		

OS MARPAT 133:252450
IT **295310-34-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(3-amidophenyl)-3,4-dihydroquinazolin-4-ones for treating diseases mediated by cytokines)
RN 295310-34-8 CAPLUS
CN 4-Pyridinecarboxamide, 2-(2,5-dihydro-1H-pyrrol-1-yl)-N-[4-methyl-3-[6-(4-methyl-1-piperazinyl)-4-oxo-3(4H)-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:456867 CAPLUS
DN 133:84284
TI A combination of fructose-1,6-bisphosphatase (FBPase) inhibitors and insulin sensitizers for the treatment of diabetes
IN Erion, Mark D.; Vanpoelje, Paul
PA Metabasis Therapeutics, Inc., USA
SO PCT Int. Appl., 306 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000038666	A2	20000706	WO 1999-US30713	19991222
	WO 2000038666	A3	20011129		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2354053	AA	20000706	CA 1999-2354053	19991222
	EP 1143955	A2	20011017	EP 1999-964313	19991222
	EP 1143955	A3	20020828		
	EP 1143955	B1	20050727		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR 9917005	A	20020402	BR 1999-17005	19991222
	JP 2003515523	T2	20030507	JP 2000-590620	19991222
	AU 771039	B2	20040311	AU 2000-20583	19991222
	RU 2227749	C2	20040427	RU 2001-120726	19991222
	NZ 512219	A	20041224	NZ 1999-512219	19991222
	EP 1552850	A2	20050713	EP 2005-8493	19991222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	AT 300288	E	20050815	AT 1999-964313	19991222
	ZA 2001005016	A	20020919	ZA 2001-5016	20010619
	NO 2001003115	A	20010824	NO 2001-3115	20010621
PRAI	US 1998-114718P	P	19981224		
	EP 1999-964313	A3	19991222		
	WO 1999-US30713	W	19991222		

OS MARPAT 133:84284
IT **261371-03-3P 280782-53-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fructose-1,6-bisphosphatase inhibitor-insulin sensitizer combination for diabetes treatment, and inhibitor preparation)

RN 261371-03-3 CAPLUS
CN Phosphonic acid, [5-[4-(aminocarbonyl)-6-methoxy-2-pyridinyl]-2-furanyl]- (9CI) (CA INDEX NAME)



RN 280782-53-8 CAPLUS
CN Phosphonic acid, [5-[4-(aminocarbonyl)-1,6-dihydro-6-oxo-2-pyridinyl]-2-furanyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:268525 CAPLUS
DN 132:279474
TI Preparation of 6-O-substituted macrolides having antibacterial activity
IN Or, Yat Sun; Clark, Richard F.; Ma, Zhenkun; Rupp, Michael John
PA Abbott Laboratories, USA
SO U.S., 37 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6054435	A	20000425	US 1999-273140	19990319

PRAI US 1999-273140 19990319
OS MARPAT 132:279474
IT **263867-83-0P 263867-87-4P 263867-88-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6-O-substituted macrolides having antibacterial activity)

RN 263867-83-0 CAPLUS
CN 3-Pyridinecarboxamide, 5-[5-[3-[[(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-ethyltetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propynyl]-2-thienyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 263867-87-4 CAPLUS
CN 3-Pyridinecarboxamide, 5-[5-[3-[[(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-ethyltetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propynyl]-2-thienyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 263867-88-5 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[5-[3-[[(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-ethyltetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propynyl]-2-thienyl]-,

2,2-dimethylhydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **263868-63-9 263868-64-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 6-O-substituted macrolides having antibacterial activity)

RN 263868-63-9 CAPLUS
CN 3-Pyridinecarboxamide, 5-(5-bromo-2-thienyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 263868-64-0 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-(5-bromo-2-thienyl)-, 2,2-dimethylhydrazide (9CI) (CA INDEX NAME)



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:175817 CAPLUS
DN 132:222529
TI Preparation of heteroaromatic phosphonates as fructose 1,6-bisphosphatase inhibitors
IN Dang, Qun; Kasibhatla, Srinivas Rao; Reddy, K. Raja; Erion, Mark D.; Reddy, M. Rami; Agarwal, Atul
PA Metabasis Therapeutics, Inc., USA
SO PCT Int. Appl., 338 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000014095	A1	20000316	WO 1999-US20346	19990903
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2343027	AA	20000316	CA 1999-2343027	19990903
	EP 1112275	A1	20010704	EP 1999-954595	19990903
	EP 1112275	B1	20030730		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9913532	A	20011002	BR 1999-13532	19990903
	JP 2002524463	T2	20020806	JP 2000-568853	19990903
	AU 761267	B2	20030529	AU 2000-10905	19990903
	NZ 510308	A	20030630	NZ 1999-510308	19990903
	AT 246197	E	20030815	AT 1999-954595	19990903
	PT 1112275	T	20031231	PT 1999-954595	19990903
	ES 2204170	T3	20040416	ES 1999-954595	19990903
	ZA 2001001711	A	20020528	ZA 2001-1711	20010228
	NO 2001001174	A	20010509	NO 2001-1174	20010307
PRAI	US 1998-135504P	P	19980909		
	US 1998-111077P	P	19981207		
	WO 1999-US20346	W	19990903		

OS MARPAT 132:222529
IT **261371-03-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of heteroarom. phosphonates as fructose 1,6-bisphosphatase inhibitors via high throughput and standard synthetic methods)
RN 261371-03-3 CAPLUS
CN Phosphonic acid, [5-[4-(aminocarbonyl)-6-methoxy-2-pyridinyl]-2-furanyl]- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 32 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:98236 CAPLUS
DN 132:151811
TI Preparation of heterocyclecarboxamides and analogs as CCR5 receptor modulators
IN Neeb, Michael J.; Bondinell, William E.; Ku, Thomas W.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006085	A2	20000210	WO 1999-US17118	19990728
	WO 2000006085	A3	20000504		
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2338697	AA	20000210	CA 1999-2338697	19990728
	EP 1102535	A2	20010530	EP 1999-937586	19990728
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002521408	T2	20020716	JP 2000-561942	19990728
	US 6399656	B1	20020604	US 2001-744629	20010409
PRAI	US 1998-94414P	P	19980728		
	US 1998-94424P	P	19980728		
	WO 1999-US17118	W	19990728		

OS MARPAT 132:151811
IT **257875-33-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclecarboxamides and analogs as CCR5 receptor modulators)
RN 257875-33-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:804348 CAPLUS
DN 132:49960
TI Preparation of amides as serotonin antagonists
IN Ito, Kiyotaka; Spiers, Glen W.; Takahashi, Fumie; Yamada, Akira; Toshima, Masaaki; Miyake, Hiroshi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 35 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11349572	A2	19991221	JP 1999-98969	19990406

PRAI AU 1998-2858 A 19980407
OS MARPAT 132:49960
IT **252927-68-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amides as serotonin antagonists)
RN 252927-68-7 CAPLUS
CN 2-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)phenyl]-4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:995215 CAPLUS
DN 124:117098
TI Preparation of pyridylanilide derivatives as fungicides
IN Riordan, Peter Dominic; Boddy, Ian Kenneth; Osbourn, Susan Elisabeth
PA Agrevo UK Ltd., UK
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9525723	A1	19950928	WO 1995-GB570	19950316

W: AU, BG, BR, CA, CN, CZ, FI, HU, JP, KR, KZ, MX, NO, NZ, PL, RO, RU, SD, SK, UA, US
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU	9518981	A1	19951009	AU 1995-18981	19950316
AU	688473	B2	19980312		
EP	750611	A1	19970102	EP 1995-911403	19950316
EP	750611	B1	19980708		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN	1143954	A	19970226	CN 1995-192131	19950316
HU	74778	A2	19970228	HU 1996-2547	19950316
HU	214292	B	19980302		
BR	9507105	A	19970909	BR 1995-7105	19950316
JP	09510471	T2	19971021	JP 1995-524455	19950316
AT	168099	E	19980715	AT 1995-911403	19950316
ZA	9502205	A	19951031	ZA 1995-2205	19950317
US	5756524	A	19980526	US 1996-714149	19960918
PRAI GB	1994-5347	A	19940318		
	WO 1995-GB570	W	19950316		

OS MARPAT 124:117098

IT **173055-92-0P 173058-10-1P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of anilide derivs. as fungicides)

RN 173055-92-0 CAPLUS
CN Benzoic acid, 2-[[[5-(3-thienyl)-3-pyridinyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 173058-10-1 CAPLUS
CN Benzoic acid, 2-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:835463 CAPLUS
DN 123:256771
TI Guanidine derivatives as inhibitors of Na+/H+ exchange in cells
IN Kuno, Atsushi; Inoue, Yoshikazu; Takasugi, Hisashi; Mizuno, Hiroaki; Yamasaki, Kumi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 212 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9426709	A1	19941124	WO 1994-JP786	19940512
	W: AU, CA, CN, HU, JP, KR, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	TW 393487	B	20000611	TW 1994-83104223	19940510
	CA 2163004	AA	19941124	CA 1994-2163004	19940512
	AU 9466912	A1	19941212	AU 1994-66912	19940512
	AU 685457	B2	19980122		
	HU 70206	A2	19950928	HU 1994-3233	19940512
	EP 699185	A1	19960306	EP 1994-914623	19940512
	EP 699185	B1	20010905		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1123545	A	19960529	CN 1994-192121	19940512
	CN 1080257	B	20020306		
	JP 08511243	T2	19961126	JP 1994-525245	19940512
	RU 2141946	C1	19991127	RU 1995-122558	19940512
	AT 205191	E	20010915	AT 1994-914623	19940512
	ES 2159558	T3	20011016	ES 1994-914623	19940512
	PT 699185	T	20020130	PT 1994-914623	19940512
	ZA 9403388	A	19950123	ZA 1994-3388	19940517
	US 5824691	A	19981020	US 1995-532804	19951109
	GR 3036549	T3	20011231	GR 2001-401402	20010906
PRAI	GB 1993-10074	A	19930517		
	GB 1993-25268	A	19931210		
	WO 1994-JP786	W	19940512		

OS MARPAT 123:256771
IT **168619-85-0P 168621-02-1P 168621-66-7P 168621-67-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(aroyl)guanidine derivs. as sodium exchange inhibitors)
RN 168619-85-0 CAPLUS
CN 3-Pyridinecarboxamide, N-(aminoiminomethyl)-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 168621-02-1 CAPLUS
CN 4-Pyridinecarboxamide, N-(aminoiminomethyl)-2-(1H-pyrrol-1-yl)- (9CI) (CA

INDEX NAME)



RN 168621-66-7 CAPLUS
CN 4-Pyridinecarboxamide, N-(aminoiminomethyl)-2-(1H-pyrrol-1-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 168621-67-8 CAPLUS
CN 2-Pyridinecarboxamide, N-(aminoiminomethyl)-4-(1H-pyrrol-1-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 36 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1982:35107 CAPLUS
DN 96:35107
TI 2(1H)-Pyridones and their use as medicines
IN Bormann, Gerhard
PA Sandoz S. A., Switz.
SO Fr. Demande, 18 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2477148	A1	19810904	FR 1981-4152	19810227

	FR 2477148	B1	19830902		
	DE 3106460	A1	19820128	DE 1981-3106460	19810221
	FI 8100558	A	19810904	FI 1981-558	19810224
	GB 2070606	A	19810909	GB 1981-6335	19810227
	GB 2070606	B2	19840229		
	WO 8102575	A1	19810917	WO 1981-CH23	19810227
	W: CH				
	NL 8100964	A	19811001	NL 1981-964	19810227
	CH 652395	A	19851115	CH 1981-7325	19810227
	BE 887737	A1	19810902	BE 1981-10154	19810302
	DK 8100944	A	19810904	DK 1981-944	19810302
	SE 8101336	A	19810904	SE 1981-1336	19810302
	AU 8167977	A1	19810910	AU 1981-67977	19810302
	JP 56135473	A2	19811022	JP 1981-28521	19810302
	ES 499971	A1	19821201	ES 1981-499971	19810302
	SU 1077567	A3	19840229	SU 1981-3254392	19810302
	IL 62246	A1	19840930	IL 1981-62246	19810302
	CA 1183533	A1	19850305	CA 1981-372050	19810302
	AT 8100960	A	19860315	AT 1981-960	19810302
	ZA 8101416	A	19821027	ZA 1981-1416	19810303
	ZA 8106211	A	19821027	ZA 1981-6211	19810303
PRAI	CH 1980-1668	A	19800303		
	CH 1980-1669	A	19800303		
	CH 1980-5717	A	19800725		
	CH 1980-7947	A	19801024		
	WO 1981-CH23	A	19810227		

IT **80391-03-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 80391-03-3 CAPLUS
CN 3-Pyridinecarboxamide, 5-(2-furanyl)-1,2-dihydro-6-methyl-2-oxo- (9CI)
(CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	126.82	294.41

STN INTERNATIONAL LOGOFF AT 14:52:31 ON 07 JAN 2006